An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
PHXM releases monthly information on total voting rights and share capital, showing stability in figures for February 2024. The company is listed on Euronext Paris and Nasdaq Global Select Market.
Positive
None.
Negative
None.
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
Article 223-16 of general regulation of French Autorité des Marchés Financiers
Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) & Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com
Date
Total of shares composing the share capital
Total of brut (1) voting rights
Total of net (2) voting rights
December 31, 2023
6 075 105
6 226 982
6 226 733
January 31, 2024
6 075 105
6 227 002
6 226 753
February 29, 2024
6 075 105
6 226 951
6 226 702
(1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights. (2) Without treasury shares.
founded in 2004, erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. erytech’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. encapsulation offers a number of benefits as compared to free-form compounds, reducing the potential for allergic reactions and allowing the therapeutic substance to remain longer in the body. its first product, working by starving tumors, has completed its phase iii development and will provide a therapeutic solution to patients with relapsed and refractory acute lymphoblastic leukemia. the company has a production unit located in lyon with “pharmaceutical establishment” status. it has signed two distribution partnership agreements, with orphan europe-recordati (in europe) and teva (in israel).
